Guardant Health, Inc.
Financials
Valuation Metrics
Guardant Health, Inc.'s Market Cap is $23.79B. At end of 2025 it was $13.14B. Ranked #524 of 3,121 in US market (top 17%), #163 of 1,463 on NASDAQ (top 11%), #39 of 205 in Health Care Equipment & Services (top 19%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $23.79B | US#524/3,121 Sec#39/205 |
| Revenue | $1.18B | US#1,791/3,121 Sec#111/205 |
| Net Income | $-453M | US—/3,121 Sec—/205 |
| Total Assets | $1.91B | US#2,118/3,121 Sec#108/205 |
| Net Assets | $-223M | US#2,995/3,121 Sec#198/205 |
| Employees | 2,498 | US#1,572/3,121 Sec#113/205 |
| Value | ||
| P/S | 20.10x | US#2,849/3,121 Sec#198/205 |
| FCF Yield | -1.01% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROA | -23.71% | US#2,840/3,121 Sec#182/205 |
| Op. Margin | -39.75% | US#2,666/3,121 Sec#177/205 |
| Revenue Growth | 42.74% | US#282/3,121 Sec#17/205 |
| Financial Health | ||
| Total Debt | $1.70B | US#1,268/3,121 Sec#63/205 |
| FCF | $-241M | US#2,813/3,121 Sec#200/205 |
| Cash | $1.05B | US#658/3,121 Sec#36/205 |
| Current Ratio | 4.03x | US#577/3,121 Sec#57/205 |
| Performance | ||
| 1Y Return | 205.07% | US#56/3,121 Sec#5/205 |
| 1M Return | 9.82% | US#153/3,121 Sec#23/205 |
| From 52W High | -2.25% | US#10/3,121 Sec#3/205 |
| 1Y MDD | -32.98% | US#1,628/3,121 Sec#82/205 |
| Trading | ||
| Volume | 2,795,814 shares | US#906/3,121 Sec#51/205 |
| Trading Value | $501M | US#285/3,121 Sec#20/205 |
| Per Share | ||
| EPS | $-3.42 | US—/3,121 Sec—/205 |
| BPS | $-1.68 | US—/3,121 Sec—/205 |
Company Info
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.